Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The lactate-NAD axis activate cancer associated fibroblasts by downregulating p62 [OLA ATAC-seq]

ABSTRACT: The lactate-NAD axis activate cancer associated fibroblasts by downregulating p62 [OLA ATAC-seq]

PROVIDER: PRJNA779990 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR16932076_1.fastq.gz	Fastqsanger.gz
	SRR16932076_2.fastq.gz	Fastqsanger.gz
	SRR16932077_1.fastq.gz	Fastqsanger.gz
	SRR16932077_2.fastq.gz	Fastqsanger.gz
	SRR16932078_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 16

Similar Datasets

The lactate-NAD axis activate cancer associated fibroblasts by downregulating p62 [OLA ATAC-seq]

Project description:Reduced p62 levels are associated with the induction of the cancer-associated fibroblast (CAF) phenotype, which promotes tumorigenesis in vitro and in vivo through inflammation and metabolic reprogramming. However, how p62 is downregulated in the stroma fibroblasts by tumor cells to drive CAF activation is an unresolved central issue in the field. Here we show that tumor-secreted lactate downregulate p62 transcriptionally through a mechanism involving reduction of the NAD+/NADH ratio, which impaired poly(ADP-Ribose)-polymerase 1 (PARP1) activity. PARP1 inhibition blocked the poly(ADP-ribosyl)ation of the AP1 transcription factors, c-FOS and c-JUN, which is an obligate step for p62 downregulation. Importantly, restoring p62 levels in CAFs by NAD+ rendered CAFs less active. PARP inhibitors, such as Olaparib, mimicked lactate in the reduction of stromal p62 levels, as well as the subsequent stromal activation both in vitro and in vivo, which suggests that therapies utilizing Olaparib would benefit from strategies aimed at inhibiting CAF activity.

2022-05-16 | GSE188719 | GEO

The lactate-NAD axis activate cancer associated fibroblasts by downregulating p62 [Lactate ATAC-seq]

2022-05-16 | GSE188718 | GEO

The lactate-NAD axis activate cancer associated fibroblasts by downregulating p62 [Quantseq]

2022-05-16 | GSE188717 | GEO

The lactate-NAD axis activate cancer associated fibroblasts by downregulating p62.

Project description:The lactate-NAD axis activate cancer associated fibroblasts by downregulating p62.

| PRJNA779984 | ENA

The lactate-NAD axis activate cancer associated fibroblasts by downregulating p62 [RNA-seq]

2022-05-16 | GSE188716 | GEO

The lactate-NAD axis activate cancer associated fibroblasts by downregulating p62 [Lactate ATAC-seq]

Project description:The lactate-NAD axis activate cancer associated fibroblasts by downregulating p62 [Lactate ATAC-seq]

| PRJNA779991 | ENA

The lactate-NAD axis activate cancer associated fibroblasts by downregulating p62 [Quantseq]

Project description:The lactate-NAD axis activate cancer associated fibroblasts by downregulating p62 [Quantseq]

| PRJNA779992 | ENA

The lactate-NAD axis activate cancer associated fibroblasts by downregulating p62 [RNA-seq]

Project description:The lactate-NAD axis activate cancer associated fibroblasts by downregulating p62 [RNA-seq]

| PRJNA779993 | ENA

The lactate-NAD axis activate cancer associated fibroblasts by downregulating p62.

Project description:This SuperSeries is composed of the SubSeries listed below.

2022-05-16 | GSE188720 | GEO

The lactate-NAD<sup>+</sup> axis activates cancer-associated fibroblasts by downregulating p62.

Project description:Reduced p62 levels are associated with the induction of the cancer-associated fibroblast (CAF) phenotype, which promotes tumorigenesis in vitro and in vivo through inflammation and metabolic reprogramming. However, how p62 is downregulated in the stroma fibroblasts by tumor cells to drive CAF activation is an unresolved central issue in the field. Here we show that tumor-secreted lactate downregulates p62 transcriptionally through a mechanism involving reduction of the NAD+/NADH ratio, which impairs poly(ADP-ribose)-polymerase 1 (PARP-1) activity. PARP-1 inhibition blocks the poly(ADP-ribosyl)ation of the AP-1 transcription factors, c-FOS and c-JUN, which is an obligate step for p62 downregulation. Importantly, restoring p62 levels in CAFs by NAD+ renders CAFs less active. PARP inhibitors, such as olaparib, mimick lactate in the reduction of stromal p62 levels, as well as the subsequent stromal activation both in vitro and in vivo, which suggests that therapies using olaparib would benefit from strategies aimed at inhibiting CAF activity.

| S-EPMC9136538 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data